CCL2 and neoplasm: Previous studies investigating chemokines associated with lymphocyte rich TMEs in melanoma observed altered expression of CCL2, CCL3, CCL4, CCL21, CXCL10, CXCL11, and CXCL13, all of which are ligands expressed by the tumor within the RDI network (Source Data)22,23.